Advanced search
Publication Cover
OncoImmunology Volume 11, 2022 - Issue 1
Submit an article Journal homepage
5,582
Views
4
CrossRef citations to date
0
Altmetric
Research Article

T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction

Jessica Pinkerta Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, GermanyView further author information
,
Hans-Henning Boehma Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, GermanyView further author information
,
Mark Trautweinb Pharmaceutical Division, Bayer AG, Wuppertal, GermanyView further author information
,
Wolf-Dietrich Doeckec Pharmaceutical Division, Bayer AG, Berlin, GermanyView further author information
,
Florian Wessela Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, GermanyView further author information
,
Yingzi Gea Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, GermanyView further author information
,
Eva Maria Gutierreza Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, GermanyView further author information
,
Rafael Carreteroa Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, GermanyView further author information
,
Christoph Freibergb Pharmaceutical Division, Bayer AG, Wuppertal, GermanyView further author information
,
Uwe Gritzand Pharmaceutical Division, Bayer AG, Cologne, GermanyView further author information
,
Merlin Luetke-Everslohc Pharmaceutical Division, Bayer AG, Berlin, GermanyView further author information
,
Sven Golfierc Pharmaceutical Division, Bayer AG, Berlin, GermanyView further author information
,
Oliver Von Ahsenc Pharmaceutical Division, Bayer AG, Berlin, GermanyView further author information
,
Valentina Volpine Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, GermanyView further author information
,
Antonio Sorrentinoe Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, GermanyView further author information
,
Anchana Rathinasamye Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, GermanyView further author information
,
Maria Xydiae Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, GermanyView further author information
,
Robert Lohmayere Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, Germany;f Institute of Theoretical Physics, University of Regensburg, Regensburg, GermanyView further author information
,
Julian Saxe Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, GermanyView further author information
,
Ayse Nur-Menevsee Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, GermanyView further author information
,
Abir Husseine Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, GermanyView further author information
,
Slava Stamovae Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, GermanyView further author information
,
Georg Beckmannc Pharmaceutical Division, Bayer AG, Berlin, GermanyView further author information
,
Julian Marius Glueckb Pharmaceutical Division, Bayer AG, Wuppertal, GermanyView further author information
,
Dorian Schoenfeldb Pharmaceutical Division, Bayer AG, Wuppertal, GermanyView further author information
,
Joerg Weiskec Pharmaceutical Division, Bayer AG, Berlin, GermanyView further author information
,
Dieter Zopfc Pharmaceutical Division, Bayer AG, Berlin, GermanyView further author information
,
Rienk Offringaa Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany;g Department of Surgery, University Hospital Heidelberg, Heidelberg, GermanyView further author information
,
Bertolt Kreftc Pharmaceutical Division, Bayer AG, Berlin, GermanyView further author information
,
Philipp Beckhovea Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany;e Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, Germany;h Hematology and Oncology Department, University Hospital Regensburg, Regensburg, GermanyCorrespondence[email protected]
View further author information
&
Joerg Willudac Pharmaceutical Division, Bayer AG, Berlin, GermanyCorrespondence[email protected]
View further author information
 show all
Article: 2008110 | Received 17 Jun 2021, Accepted 15 Nov 2021, Published online: 30 Dec 2021

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.